Author: admin

Operations: The company’s revenue is primarily derived from its immunotherapy segment, which generated A$5.03 million.

Market Cap: A$552.65M

Immutep Limited, a biotechnology company with a market cap of A$552.65 million, is focused on developing immunotherapies and has recently entered into a strategic collaboration with Dr. Reddy’s Laboratories for the development and commercialization of its lead product, eftilagimod alfa (efti), in selected markets. The agreement includes an upfront payment of US$20 million and potential milestone payments up to US$349.5 million, alongside double-digit royalties on sales. Despite being pre-revenue with A$5 million in revenue from its immunotherapy segment, Immutep’s strong cash position exceeds both short-term and long-term liabilities, supporting ongoing clinical trials for various cancers.

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Wagners Holding Company Limited produces and sells construction and related building materials across several countries, including Australia, the United States, New Zealand, the United Kingdom, Papua New Guinea, and Malaysia; it has a market cap of A$719.01 million.

Operations: Wagners Holding generates revenue through its Construction Materials segment at A$257.69 million, Project Services at A$105.71 million, Earth Friendly Concrete at A$0.16 million, and Composite Fibre Technology at A$68.45 million.

Market Cap: A$719.01M

Wagners Holding, with a market cap of A$719.01 million, has shown robust financial health and growth potential. Its interest payments are well covered by EBIT, and the net debt to equity ratio of 12.6% is satisfactory. The company has experienced management and board teams with average tenures over eight years. While short-term assets cover short-term liabilities, they fall short for long-term obligations. However, Wagners’ debt reduction over five years and substantial earnings growth of 120.9% last year indicate strong operational performance in its construction materials segment, supported by inclusion in the S&P/ASX Emerging Companies Index recently.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:DUG ASX:IMM and ASX:WGN.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com